Effect of Discontinuation of 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Men With BPH: A Prospective Study

Urology

Volumn 73, Issue 4, 2009, Pages 802-806

  Jeong, Young Beom ^a   Kwon, Keun Sang ^a   Kim, Sang Deuk ^a   Kim, Hyung Jin ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; CHOLESTENONE 5ALPHA REDUCTASE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PROSTATE; RANDOMIZED CONTROLLED TRIAL;

CHOLESTENONE 5 ALPHA-REDUCTASE; DRUG THERAPY, COMBINATION; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC HYPERPLASIA; SEVERITY OF ILLNESS INDEX;

EID: 63149122266     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.046     Document Type: Article

References (23)

1. Clark R.V., Hermann D.J., Cunningham G.R., et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5a-reductase inhibitor. J Clin Endocrinol Metab 89 (2004) 2179-2184
2. Roehrborn C.G., Boyle P., Nickel J.C., et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
3. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2396
4. Roehrborn C.G., Bruskewitz R., Nickel J.C., et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 171 (2004) 1194-1198
5. Debruyne F., Barkin J., van Erps P., et al. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 (2004) 488-494
6. Boyle P., Roehrborn C., Harkaway R., et al. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 45 (2004) 620-626
7. Andersen J.T., Nickel J.C., Marshall V.R., et al. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49 (1997) 839-845
8. Roehrborn C.G., Siami P., Barkin J., et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the combat study. J Urol 179 (2008) 616-621
9. Li N.C., Chen S., Yang X.H., et al. Efficacy of low-dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Invest 23 (2003) 781-787
10. Emberton M., Andriole G.L., de la Rosette J., et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61 (2003) 267-273
11. Roehrborn C.G., and McConnell J.D. Benign prostatic hyperplasia: etiology, pathophysiology, epidemiology, and natural history. In: Kavoussi L.R., Novick A.C., Partin A.W., et al. (Eds). Campbell-Walsh Urology vol. 3 (2007), Elsevier Saunders, Philadelphia 2727-2734
12. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40-79 years old. J Urol 161 (1999) 1174-1179
13. Roberts R.O., Jacobsen S.J., Jacobson D.J., et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 163 (2000) 107-113
14. Arrighi H.M., Metter E.J., Guess H.A., et al. Natural history of benign prostatic hyperplasia and risk of prostatectomy: the Baltimore Longitudinal Study of Aging. Urology 38 suppl 1 (1991) 4-8
15. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
16. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol 162 (1999) 1301-1306
17. Arrighi H.M., Guess H.A., Metter E.J., et al. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 16 (1990) 253-261
18. Peters C.A., and Walsh P.C. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 317 (1987) 599-604
19. Stoner E., and Finasteride Study Group. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. J Urol 147 (1992) 1298-1302
20. Roehrborn C.G. 5-Alpha-reductase inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol 5 suppl 5 (2003) S12-S21
21. Madersbacher S., Marszalek M., Lackner J., et al. The long-term outcome of medical therapy for BPH. Eur Urol 51 (2007) 1522-1533
22. Sandhu J.S., and Te A.E. The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep 5 (2004) 274-279
23. Nickel J.C., Barkin J., Koch C., et al. Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers. Can Urol Assoc J 2 (2008) 16-21